FDA Approves First At-Home FluMist for Self-Administration

Sep 20, 2024, 05:32 PM

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration. This makes FluMist the first influenza vaccine that can be administered without the need for a healthcare provider. The approval, announced on Friday, covers individuals aged 2 through 49 years and aims to expand consumer access to medicines, reduce costs, and lower barriers to care. The vaccine will be available through third-party pharmacies, where individuals will complete a screening and eligibility assessment when ordering the vaccine. The approval also marks the first at-home flu vaccine in the U.S.